Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Saved in:
| Title: | Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. |
|---|---|
| Authors: | Mai EK; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Goldschmid H; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany. Electronic address: hartmut.goldschmidt@med.uni-heidelberg.de., Miah K; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Bertsch U; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany., Besemer B; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany., Hänel M; Department of Internal Medicine III, Clinic Chemnitz, Chemnitz, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Fenk R; Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Schlenzka J; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Munder M; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany., Dürig J; Department for Haematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany., Huhn S; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Hose D; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Kunz C; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Mann C; Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany., Weinhold N; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Scheid C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Schroers R; Medical Clinic, University Hospital Bochum, Bochum, Germany., von Metzler I; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Schieferdecker A; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Thomalla J; Haematology-Oncology Centre, Koblenz, Germany., Reimer P; Clinic for Haematology, Oncology and Stem Cell Transplantation, Evangelische Kliniken Essen-Mitte, Essen, Germany., Mahlberg R; Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany., Graeven U; Medical Clinic I, Hospital Maria Hilf, Mönchengladbach, Germany., Kremers S; Haematology-Oncology Centre, Lebach, Germany., Martens UM; Haematology, Oncology, Palliative Care, SLK Clinic Heilbronn, Heilbronn, Germany., Kunz C; Haematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany., Hensel M; Mannheimer Onkologie Praxis, Mannheim, Germany., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Seidel-Glätzer A; Coordination Centre for Clinical Trials Heidelberg, Heidelberg, Germany., Weisel KC; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Raab MS; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Salwender HJ; Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St Georg, Hamburg, Germany. |
| Corporate Authors: | German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators |
| Source: | The Lancet. Haematology [Lancet Haematol] 2024 Feb; Vol. 11 (2), pp. e101-e113. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38302221 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mai+EK%22">Mai EK</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Goldschmid+H%22">Goldschmid H</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany. Electronic address: hartmut.goldschmidt@med.uni-heidelberg.de.<br /><searchLink fieldCode="AU" term="%22Miah+K%22">Miah K</searchLink>; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Bertsch+U%22">Bertsch U</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Besemer+B%22">Besemer B</searchLink>; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22Hänel+M%22">Hänel M</searchLink>; Department of Internal Medicine III, Clinic Chemnitz, Chemnitz, Germany.<br /><searchLink fieldCode="AU" term="%22Krzykalla+J%22">Krzykalla J</searchLink>; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Fenk+R%22">Fenk R</searchLink>; Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Schlenzka+J%22">Schlenzka J</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Munder+M%22">Munder M</searchLink>; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Dürig+J%22">Dürig J</searchLink>; Department for Haematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Blau+IW%22">Blau IW</searchLink>; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Huhn+S%22">Huhn S</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Hose+D%22">Hose D</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Jauch+A%22">Jauch A</searchLink>; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Kunz+C%22">Kunz C</searchLink>; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Mann+C%22">Mann C</searchLink>; Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Weinhold+N%22">Weinhold N</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Scheid+C%22">Scheid C</searchLink>; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Schroers+R%22">Schroers R</searchLink>; Medical Clinic, University Hospital Bochum, Bochum, Germany.<br /><searchLink fieldCode="AU" term="%22von+Metzler+I%22">von Metzler I</searchLink>; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Schieferdecker+A%22">Schieferdecker A</searchLink>; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Thomalla+J%22">Thomalla J</searchLink>; Haematology-Oncology Centre, Koblenz, Germany.<br /><searchLink fieldCode="AU" term="%22Reimer+P%22">Reimer P</searchLink>; Clinic for Haematology, Oncology and Stem Cell Transplantation, Evangelische Kliniken Essen-Mitte, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Mahlberg+R%22">Mahlberg R</searchLink>; Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany.<br /><searchLink fieldCode="AU" term="%22Graeven+U%22">Graeven U</searchLink>; Medical Clinic I, Hospital Maria Hilf, Mönchengladbach, Germany.<br /><searchLink fieldCode="AU" term="%22Kremers+S%22">Kremers S</searchLink>; Haematology-Oncology Centre, Lebach, Germany.<br /><searchLink fieldCode="AU" term="%22Martens+UM%22">Martens UM</searchLink>; Haematology, Oncology, Palliative Care, SLK Clinic Heilbronn, Heilbronn, Germany.<br /><searchLink fieldCode="AU" term="%22Kunz+C%22">Kunz C</searchLink>; Haematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany.<br /><searchLink fieldCode="AU" term="%22Hensel+M%22">Hensel M</searchLink>; Mannheimer Onkologie Praxis, Mannheim, Germany.<br /><searchLink fieldCode="AU" term="%22Benner+A%22">Benner A</searchLink>; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Seidel-Glätzer+A%22">Seidel-Glätzer A</searchLink>; Coordination Centre for Clinical Trials Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Weisel+KC%22">Weisel KC</searchLink>; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Raab+MS%22">Raab MS</searchLink>; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Salwender+HJ%22">Salwender HJ</searchLink>; Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St Georg, Hamburg, Germany. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22German-speaking+Myeloma+Multicenter+Group+%28GMMG%29+HD6+investigators%22">German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2024 Feb; Vol. 11 (2), pp. e101-e113. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38302221 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(23)00366-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e101 Titles: – TitleFull: Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mai EK – PersonEntity: Name: NameFull: Goldschmid H – PersonEntity: Name: NameFull: Miah K – PersonEntity: Name: NameFull: Bertsch U – PersonEntity: Name: NameFull: Besemer B – PersonEntity: Name: NameFull: Hänel M – PersonEntity: Name: NameFull: Krzykalla J – PersonEntity: Name: NameFull: Fenk R – PersonEntity: Name: NameFull: Schlenzka J – PersonEntity: Name: NameFull: Munder M – PersonEntity: Name: NameFull: Dürig J – PersonEntity: Name: NameFull: Blau IW – PersonEntity: Name: NameFull: Huhn S – PersonEntity: Name: NameFull: Hose D – PersonEntity: Name: NameFull: Jauch A – PersonEntity: Name: NameFull: Kunz C – PersonEntity: Name: NameFull: Mann C – PersonEntity: Name: NameFull: Weinhold N – PersonEntity: Name: NameFull: Scheid C – PersonEntity: Name: NameFull: Schroers R – PersonEntity: Name: NameFull: von Metzler I – PersonEntity: Name: NameFull: Schieferdecker A – PersonEntity: Name: NameFull: Thomalla J – PersonEntity: Name: NameFull: Reimer P – PersonEntity: Name: NameFull: Mahlberg R – PersonEntity: Name: NameFull: Graeven U – PersonEntity: Name: NameFull: Kremers S – PersonEntity: Name: NameFull: Martens UM – PersonEntity: Name: NameFull: Kunz C – PersonEntity: Name: NameFull: Hensel M – PersonEntity: Name: NameFull: Benner A – PersonEntity: Name: NameFull: Seidel-Glätzer A – PersonEntity: Name: NameFull: Weisel KC – PersonEntity: Name: NameFull: Raab MS – PersonEntity: Name: NameFull: Salwender HJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2024 Feb Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 11 – Type: issue Value: 2 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
